Dosing has begun in a Phase 2 clinical trial evaluating aTyr Pharma’s efzofitimod, a first-in-class therapy for people with interstitial lung disease (ILD) associated with systemic sclerosis (SSc) — together known as SSc-ILD. Recruitment for the proof-of-concept EFZO-CONNECT study (NCT05892614), which aims to enroll up to 25…
News
Including intravenous immunoglobulin (IVIG) as part of routine care may help to ease muscle, skin, and digestive symptoms in people with systemic sclerosis (SSc), a Spanish study found. The experimental treatment was seen to be generally safe, with reported side effects being mostly mild or moderate. While these findings…
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to FT011, an experimental oral medication that Certa Therapeutics is developing as a treatment for systemic sclerosis. The FDA gives this designation to investigational treatments for rare diseases, those affecting fewer than 200,000 people…
Kyverna Therapeutics is launching a Phase 1/2 trial to evaluate its investigational cell therapy KYV-101 in adults with diffuse cutaneous systemic sclerosis (dcSSc). The move follows the therapy’s recent clearance of an investigational new drug (IND) application by the U.S. Food and Drug Administration (FDA). The trial, called…
Boehringer Ingelheim has joined the CONQUEST platform trial, adding a second experimental medication to the multidrug study launched by the Scleroderma Research Foundation (SRF) to speed therapy development for interstitial lung disease (ILD) associated with scleroderma (SSc). In a platform trial, a master protocol is used…
The U.S. Food and Drug Administration (FDA) has cleared Cabaletta Bio’s request to begin clinical testing of CABA-201, a cell therapy for adults with hard-to-treat systemic sclerosis (SSc). Cabaletta now plans to launch a Phase 1/2 clinical trial, enrolling SSc patients with severe skin manifestations or organ…
A prediction tool known as nomogram may be used to calculate the chance of a person with systemic sclerosis (SSc) and interstitial lung disease (ILD) developing progressive pulmonary fibrosis, or worsening lung scarring, a new study suggests. The nomogram essentially is a pictorial representation of a complex mathematical…
Blood levels of interleukin (IL)-6, a pro-inflammatory signaling molecule, do not link with a risk of pulmonary involvement in people with systemic sclerosis (SSc), a study reports. As a result, IL-6 “could not be regarded as a potential therapeutic target,” the researchers wrote in the study, “…
Arsenic trioxide (ATO) lowered lung inflammation and disease-related alterations to blood vessels in the lungs in a mouse model of scleroderma (SSc), a study reports. “Our study provides compelling evidence of the positive effects of ATO treatment on lung function in a mouse model of SSc,” researchers wrote in…
Antibodies designed to neutralize the protein galectin-3 (Gal-3) eased scarring and inflammation in a mouse model of systemic sclerosis (SSc), a recent study shows. Gene activity related to Gal-3 and the proteins it interacts with were found to be strongly associated with disease severity, lung and heart malfunction, and…
Recent Posts
- Genetic links to systemic sclerosis may differ by sex, new study finds
- Autoantibodies tied to symptoms, complications in scleroderma study
- Liver enzyme levels help diagnose autoimmune hepatitis in SSc: Study
- Stem cell transplant safely eases scleroderma symptoms for teen
- New study flags existing medications as possible scleroderma treatments
- Anti-CD146 antibodies may signal occupational exposure in SSc: Study
- New SSc drug safely cuts Raynaud’s attack duration, eases symptoms
- Carbon dioxide hand baths may help in SSc-related Raynaud’s, study finds
- More SSc-ILD patients receive early treatment, new study finds
- CD13 levels elevated in scleroderma, but biomarker value unclear